CXM Financial Facts
Net loss: -1.19MTotal operating expenses: 1.19M
See Full Income Statement
Total liabilities: 3.41M
Additional paid-in capital: 110.74M
See Full Balance Sheet
Cardium Therapeutics, Inc. (CXM) Earnings
|
Expand Research on CXM
| Next EPS Date | 6/4/24 | EPS Growth Rate | +16.7% |
|---|---|---|---|
| Average EPS % Beat Rate | +179.0% | Revenue Growth Rate | +12.1% |
| Average % Move 1-Wk after EPS | -9.8% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/14/13 | Q212 | -$0.37 | -$0.20 | -$0.17 | $584.57K | $1M | N/A |  | | Details | |
| 9/8/22 | Q222 | -$0.09 | -$0.06 | -$0.03 | $118.69M | $147.46M | = | | | Details | |
| 12/9/21 |  |
Q321 | -$0.06 | -$0.09 | +$0.03 | $127.1M | $120.24M | = | | | Details |
| 6/14/22 | |
Q122 | -$0.05 | -$0.06 | +$0.01 | $145M | $141.1M | = | | | Details |
| 4/6/22 | |
Q421 | -$0.05 | -$0.09 | +$0.04 | $136M | $130.38M | = | | | Details |
| 3/30/12 | Q411 | -$0.02 | N/A | N/A | N/A | N/A | N/A | | | Details | |
| 5/15/12 | Q112 | -$0.02 | N/A | N/A | N/A | N/A | N/A | | | Details | |
9/9/21  |
|
Q221 | N/A | -$0.13 | N/A | N/A | $109.29M | = | N/A | N/A |
